CABA-201: Clinical Trials

4 recruiting, 1 withdrawn. 5 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS)	Phase 1 / Phase 2	Withdrawn	Cabaletta Bio		2026-06-01	2026-06-25
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis CABA-201 - Generalized Myasthenia Gravis (gMG)	Phase 1 / Phase 2	Recruiting	Cabaletta Bio	24	2024-12-17	2026-10-19
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis CABA-201 - Systemic Sclerosis, Scleroderma	Phase 2 / Phase 3	Recruiting	Cabaletta Bio	37	2024-07-02	2026-10-16
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus CABA-201 - Systemic Lupus Erythematosus, Lupus Nephritis	Phase 1 / Phase 2	Recruiting	Cabaletta Bio	28	2024-02-16	2026-10-06
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) DSG3-CAART, CABA-201 - Pemphigus Vulgaris	Phase 1 / Phase 2	Recruiting	Cabaletta Bio	40	2020-09-29	2026-10-15